Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry
Journal
Respiratory medicine
Journal Volume
178
Pages
106220
Date Issued
2021-03
Author(s)
Ghofrani, Hossein-Ardeschir
Gomez Sanchez, Miguel-Angel
Humbert, Marc
Pittrow, David
Simonneau, Gérald
Gall, Henning
Grünig, Ekkehard
Klose, Hans
Halank, Michael
Langleben, David
Snijder, Repke J
Escribano Subias, Pilar
Mielniczuk, Lisa M
Lange, Tobias J
Vachiéry, Jean-Luc
Wirtz, Hubert
Helmersen, Douglas S
Tsangaris, Iraklis
Barberá, Joan A
Pepke-Zaba, Joanna
Boonstra, Anco
Rosenkranz, Stephan
Ulrich, Silvia
Steringer-Mascherbauer, Regina
Delcroix, Marion
Jansa, Pavel
Šimková, Iveta
Giannakoulas, George
Klotsche, Jens
Williams, Evgenia
Meier, Christian
Hoeper, Marius M
Abstract
The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice.
Subjects
Chronic thromboembolic pulmonary hypertension; Clinical practice; Real-world; Registry; Riociguat; Safety
SDGs
Other Subjects
ambrisentan; bosentan; guanylate cyclase; iloprost; macitentan; prostacyclin; prostanoid; riociguat; treprostinil; pyrazole derivative; pyrimidine derivative; riociguat; adverse event; aged; Article; chronic thromboembolic pulmonary hypertension; clinical practice; clinical trial; cohort analysis; combination drug therapy; disease registry; dizziness; drug safety; dyspnea; faintness; female; heart right ventricle failure; hemoptysis; human; hypotension; lung hemorrhage; major clinical study; male; Medical Dictionary for Regulatory Activities; monotherapy; multicenter study; peripheral edema; phase 3 clinical trial; pneumonia; priority journal; prospective study; pulmonary hypertension; randomized controlled trial; chronic disease; complication; data analysis; lung embolism; middle aged; multicenter study (topic); pulmonary hypertension; randomized controlled trial (topic); recurrent disease; register; safety; time factor; treatment outcome; Aged; Chronic Disease; Data Analysis; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Recurrence; Registries; Safety; Time Factors; Treatment Outcome
Type
journal article